AGENERASE DIN 02243541
Health Canada record
| Active ingredient(s) | AMPRENAVIR 50 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AE05 AMPRENAVIR |
| Original market date | 21-Mar-2001 |
| Current status date | 27-May-2008 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AMPRENAVIR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02243542 | AGENERASE | GLAXOSMITHKLINE INC | Capsule | AMPRENAVIR 150 MG | Cancelled Post Market |
| 02243543 | AGENERASE | GLAXOSMITHKLINE INC | Liquid | AMPRENAVIR 15 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 764 | 2001-11-21 | New Drug Submission (NDS) | CHANGE IN MANUFACTURER NAME |
| 1690 | 2001-03-01 | New Drug Submission (NDS) |
International API supply for AMPRENAVIR
1 active FDA Drug Master Files.
Request a quote for AGENERASE